Menu

Report Library

All Reports
Datamonitor Healthcare Strategy: Innovation in Deal-Making

Retail Price: $2,995.00

*BioMedTracker Subscriber Price: $2,095.00 - click here to log in

June 13, 2018

In order to continually and effectively compete with its peers, as well as with smaller specialty pharmaceutical companies and biotechnology companies, the top 20 global pharmaceutical peer set turns to deal-making as a means to balance out its internally developed portfolio, and to take advantage of the broader capabilities of partners or takeover targets. Through both alliances and therapeutically driven bolt-on acquisitions, the top 20 companies have in-licensed, co-developed, and acquired important assets to help advance their strategies.

This Datamonitor Healthcare report contains a Strategy module.

Disease Group Covered: Autoimmune/immunology
Endocrine
Neurology
Oncology
Back to the top Back to the top